Cancer Immunotherapy with CDK7 Inhibitors.
Recent findings demonstrate that pharmacological cyclin-dependent kinase 7 (CDK7) inhibitors can evoke anticancer immunity upon genomic destabilization of neoplastic cells. Besides adding CDK7 to the expanding list of cell cycle proteins that impinge on immune regulation, these results support the value of aggravating genomic instability in cancer cells to enable immunological disease control.
['Petroni|Giulia|G|', 'Galluzzi|Lorenzo|L|']
D042822:Genomic Instability D006801:Humans D007167:Immunotherapy D009369:Neoplasms
PD-1 YKL-5-124 immune checkpoint blockade micronuclei small cell lung cancer type I interferon